139 related articles for article (PubMed ID: 26163623)
1. LCN2 Promoter Methylation Status as Novel Predictive Marker for Microvessel Density and Aggressive Tumor Phenotype in Breast Cancer Patients.
Meka Pb; Jarjapu S; Nanchari SR; Vishwakarma SK; Edathara PM; Gorre M; Cingeetham A; Vuree S; Annamaneni S; Dunna NR; Mukta S; B T; Satti V
Asian Pac J Cancer Prev; 2015; 16(12):4965-9. PubMed ID: 26163623
[TBL] [Abstract][Full Text] [Related]
2. Lipocalin 2, the TNF-like receptor TWEAKR and its ligand TWEAK act downstream of NFAT1 to regulate breast cancer cell invasion.
Gaudineau B; Fougère M; Guaddachi F; Lemoine F; de la Grange P; Jauliac S
J Cell Sci; 2012 Oct; 125(Pt 19):4475-86. PubMed ID: 22767506
[TBL] [Abstract][Full Text] [Related]
3. Long-term low-dose exposure of human urothelial cells to sodium arsenite activates lipocalin-2 via promoter hypomethylation.
Wang HH; Wu MM; Chan MW; Pu YS; Chen CJ; Lee TC
Arch Toxicol; 2014 Aug; 88(8):1549-59. PubMed ID: 24570342
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor (ER)α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression.
Drew BG; Hamidi H; Zhou Z; Villanueva CJ; Krum SA; Calkin AC; Parks BW; Ribas V; Kalajian NY; Phun J; Daraei P; Christofk HR; Hewitt SC; Korach KS; Tontonoz P; Lusis AJ; Slamon DJ; Hurvitz SA; Hevener AL
J Biol Chem; 2015 Feb; 290(9):5566-81. PubMed ID: 25468909
[TBL] [Abstract][Full Text] [Related]
5. Lipocalin 2 expression is associated with aggressive features of endometrial cancer.
Mannelqvist M; Stefansson IM; Wik E; Kusonmano K; Raeder MB; Øyan AM; Kalland KH; Moses MA; Salvesen HB; Akslen LA
BMC Cancer; 2012 May; 12():169. PubMed ID: 22559235
[TBL] [Abstract][Full Text] [Related]
6. Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors.
Czekierdowski A; Czekierdowska S; Danilos J; Czuba B; Sodowski K; Sodowska H; Szymanski M; Kotarski J
J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():53-65. PubMed ID: 18955754
[TBL] [Abstract][Full Text] [Related]
7. Relationship of SNCG, S100A4, S100A9 and LCN2 gene expression and DNA methylation in bladder cancer.
Dokun OY; Florl AR; Seifert HH; Wolff I; Schulz WA
Int J Cancer; 2008 Dec; 123(12):2798-807. PubMed ID: 18803290
[TBL] [Abstract][Full Text] [Related]
8. ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner.
Mahadevan NR; Rodvold J; Almanza G; Pérez AF; Wheeler MC; Zanetti M
BMC Cancer; 2011 Jun; 11():229. PubMed ID: 21649922
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis.
Leng X; Ding T; Lin H; Wang Y; Hu L; Hu J; Feig B; Zhang W; Pusztai L; Symmans WF; Wu Y; Arlinghaus RB
Cancer Res; 2009 Nov; 69(22):8579-84. PubMed ID: 19887608
[TBL] [Abstract][Full Text] [Related]
10. Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer.
Chung IH; Chen CY; Lin YH; Chi HC; Huang YH; Tai PJ; Liao CJ; Tsai CY; Lin SL; Wu MH; Chen CY; Lin KH
Oncotarget; 2015 Jun; 6(17):15050-64. PubMed ID: 25940797
[TBL] [Abstract][Full Text] [Related]
11. HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2.
Cheng G; Sun X; Wang J; Xiao G; Wang X; Fan X; Zu L; Hao M; Qu Q; Mao Y; Xue Y; Wang J
Cancer Res; 2014 Feb; 74(3):862-72. PubMed ID: 24295734
[TBL] [Abstract][Full Text] [Related]
12. NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene.
Fougère M; Gaudineau B; Barbier J; Guaddachi F; Feugeas JP; Auboeuf D; Jauliac S
Oncogene; 2010 Apr; 29(15):2292-301. PubMed ID: 20101218
[TBL] [Abstract][Full Text] [Related]
13. Lipocalin 2 promotes breast cancer progression.
Yang J; Bielenberg DR; Rodig SJ; Doiron R; Clifton MC; Kung AL; Strong RK; Zurakowski D; Moses MA
Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3913-8. PubMed ID: 19237579
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of lipocalin-2 suppresses the growth and invasion of prostate cancer cells.
Tung MC; Hsieh SC; Yang SF; Cheng CW; Tsai RT; Wang SC; Huang MH; Hsieh YH
Prostate; 2013 Sep; 73(12):1281-90. PubMed ID: 23775308
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic induction of epithelial to mesenchymal transition by LCN2 mediates metastasis and tumorigenesis, which is abrogated by NF-κB inhibitor BRM270 in a xenograft model of lung adenocarcinoma.
Mongre RK; Sodhi SS; Sharma N; Ghosh M; Kim JH; Kim N; Park YH; Shin YG; Kim SJ; Jiao ZJ; Huynh do L; Jeong DK
Int J Oncol; 2016 Jan; 48(1):84-98. PubMed ID: 26573874
[TBL] [Abstract][Full Text] [Related]
16. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway.
Wang YP; Yu GR; Lee MJ; Lee SY; Chu IS; Leem SH; Kim DG
Hepatology; 2013 Oct; 58(4):1349-61. PubMed ID: 23696034
[TBL] [Abstract][Full Text] [Related]
17. The role of lipocalin-2 in liver regeneration.
Kienzl-Wagner K; Moschen AR; Geiger S; Bichler A; Aigner F; Brandacher G; Pratschke J; Tilg H
Liver Int; 2015 Apr; 35(4):1195-202. PubMed ID: 25040147
[TBL] [Abstract][Full Text] [Related]
18. Effect of NUCKS-1 overexpression on cytokine profiling in obese women with breast cancer.
Soliman NA; Zineldeen DH; El-Khadrawy OH
Asian Pac J Cancer Prev; 2014; 15(2):837-45. PubMed ID: 24568505
[TBL] [Abstract][Full Text] [Related]
19. Lipocalin-2 elicited by advanced glycation end-products promotes the migration of vascular smooth muscle cells.
Chung TW; Choi HJ; Kim CH; Jeong HS; Ha KT
Biochim Biophys Acta; 2013 Dec; 1833(12):3386-3395. PubMed ID: 24149112
[TBL] [Abstract][Full Text] [Related]
20. Lipocalin (LCN) 2 Mediates Pro-Atherosclerotic Processes and Is Elevated in Patients with Coronary Artery Disease.
Oberoi R; Bogalle EP; Matthes LA; Schuett H; Koch AK; Grote K; Schieffer B; Schuett J; Luchtefeld M
PLoS One; 2015; 10(9):e0137924. PubMed ID: 26367277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
